U.S., Aug. 29 -- ClinicalTrials.gov registry received information related to the study (NCT07791576) titled 'Population PK-guided ATG Dosing in Haplo-HSCT' on Aug. 19.
Brief Summary: To evaluate the safety and efficacy of a population pharmacokinetics (PK)-guided targeted ATG dosing strategy in haploidentical stem cell transplantation and to observe the GVHD-free, relapse-free survival (GRFS) in the cohort receiving this strategy.
Study Start Date: May 10, 2025
Study Type: INTERVENTIONAL
Condition:
Hematopoietic Stem Cell Transplantation
Intervention:
DRUG: Anti Thymocyte Globulin
Population pharmacokinetic formula-guided targeted ATG dosing plus classical GVHD prophylaxis regimen
Recruitment Status: RECRUITING
Sponsor: Chinese PL...